Skip to main content

Advertisement

SpringerLink
Log in

Comprehensive Profiling of EGFR/HER Receptors for Personalized Treatment of Gynecologic Cancers

  • Review Article
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

The primary gynecologic cancers include cancers of the endometrium, ovary, and cervix. Worldwide, cervical cancer is the most common gynecologic cancer, whereas endometrial cancer is the most common in the US. Ovarian cancer is the fifth most deadly cancer in women, with 5-year survival rates for advanced disease at only 27 %. As such, there is an urgent need for reliable screening tools and novel targeted therapeutic regimens for these malignancies. The epidermal growth factor receptor (EGFR)/human EGFR (HER) family of receptors has been associated with the development and progression of many solid tumors. Despite clear roles for these receptors in other cancers, the expression of HER family members in gynecologic cancers and their relationship with disease stage, grade, and response to treatment remain controversial. In this review, we describe the existing evidence for the use of HER family members as diagnostic and prognostic indicators as well as their potential as therapeutic targets in gynecologic cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA. 1989;86(23):9193–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012;127(2):345–50.

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.

    CAS  PubMed  Google Scholar 

  4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.

    CAS  PubMed  Google Scholar 

  5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306–11.

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10(1):25–38.

    PubMed  Google Scholar 

  7. Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA. 2012;109(36):14476–81.

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3(2):224–37.

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445(7126):437–41.

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–43.

    CAS  PubMed  Google Scholar 

  11. Jiang N, Saba NF, Chen ZG. Advances in targeting HER3 as an anticancer therapy. Chemother Res Pract. 2012;2012:817304.

    PubMed Central  PubMed  Google Scholar 

  12. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem. 2000;275(12):8641–9.

    CAS  PubMed  Google Scholar 

  13. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001;294(5549):2179–81.

    CAS  PubMed  Google Scholar 

  14. Hollmen M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schoffski P, Elenius K. Proteolytic processing of ErbB4 in breast cancer. PLoS ONE. 2012;7(6):e39413.

    CAS  PubMed Central  PubMed  Google Scholar 

  15. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–15.

    CAS  PubMed  Google Scholar 

  16. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, Yamada T, Kikuchi Y, Honjo H, Matsubara O. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci. 2003;94(11):986–91.

    CAS  PubMed  Google Scholar 

  17. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer. 1995;76(10 Suppl):2034–40.

    CAS  PubMed  Google Scholar 

  18. Karam A, Berek JS, Stenson A, Rao J, Dorigo O. HER-2/neu targeting for recurrent vulvar Paget’s disease: a case report and literature review. Gynecol Oncol. 2008;111(3):568–71.

    CAS  PubMed  Google Scholar 

  19. Poller DN, Spendlove I, Baker C, Church R, Ellis IO, Plowman GD, Mayer RJ. Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas. J Pathol. 1992;168(3):275–80.

    CAS  PubMed  Google Scholar 

  20. Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg. 2010;251(6):1107–16.

    PubMed  Google Scholar 

  21. Gilmour LM, Macleod KG, McCaig A, Gullick WJ, Smyth JF, Langdon SP. Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res. 2001;61(5):2169–76.

    CAS  PubMed  Google Scholar 

  22. Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst. 2009;101(21):1453–63.

    PubMed Central  PubMed  Google Scholar 

  23. Shi SR, Liu C, Taylor CR. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem. 2007;55(2):105–9.

    CAS  PubMed  Google Scholar 

  24. Eriksen JG. T. Steiniche, J. Overgaard, H. Danish, and g. Neck Cancer study, The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol. 2005;44(1):50–8.

    CAS  PubMed  Google Scholar 

  25. Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast. 2012;21(1):20–6.

    CAS  PubMed  Google Scholar 

  26. Wang DP, Konishi I, Koshiyama M, Nanbu Y, Iwai T, Nonogaki H, Mori T, Fujii S. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. Virchows Arch A Pathol Anat Histopathol. 1992;421(5):393–400.

    CAS  PubMed  Google Scholar 

  27. Gui T, Shen K. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol. 2012;36(5):490–6.

    CAS  PubMed  Google Scholar 

  28. Goff BA, Shy K, Greer BE, Muntz HG, Skelly M, Gown AM. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer. Eur J Gynaecol Oncol. 1996;17(6):487–92.

    CAS  PubMed  Google Scholar 

  29. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer. 2004;14(2):259–70.

    CAS  PubMed  Google Scholar 

  30. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008;1785(2):232–65.

    CAS  PubMed  Google Scholar 

  31. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I–II) epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001;11(2):119–29.

    CAS  PubMed  Google Scholar 

  32. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer. 2008;98(6):1076–84.

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L, Riehle D, Wang HJ, Dowdy S, Podratz KC, Press MF. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009;100(1):89–95.

    CAS  PubMed Central  PubMed  Google Scholar 

  34. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(3):486–94.

    CAS  PubMed  Google Scholar 

  35. Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol. 2008;32(2):307–16.

    CAS  PubMed  Google Scholar 

  36. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol. 1990;76(3 Pt 1):381–7.

    CAS  PubMed  Google Scholar 

  37. Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol. 2011;22(10):2166–78.

    CAS  PubMed  Google Scholar 

  38. Noordhuis MG, Eijsink JJ, Roossink F, de Graeff P, Pras E, Schuuring E, Wisman GB, de Bock GH, van der Zee AG. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review. Int J Radiat Oncol Biol Phys. 2011;79(2):325–34.

    CAS  PubMed  Google Scholar 

  39. Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol. 2004;95(3):570–5.

    CAS  PubMed  Google Scholar 

  40. Karlan BY. Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? J Cell Biochem Suppl. 1995;23:227–32.

    CAS  PubMed  Google Scholar 

  41. Auranen A, Grenman S, Kleml PJ. Immunohistochemically detected p53 and HER-2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas. Cancer. 1997;79(11):2147–53.

    CAS  PubMed  Google Scholar 

  42. Buller RE, Anderson B, Connor JP, Robinson R. Familial ovarian cancer. Gynecol Oncol. 1993;51(2):160–6.

    CAS  PubMed  Google Scholar 

  43. Cane P, Azen C, Lopez E, Platt LD, Karlan BY. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. Gynecol Oncol. 1995;57(2):240–5.

    CAS  PubMed  Google Scholar 

  44. Cheung TH, Wong YF, Chung TK, Maimonis P, Chang AM. Clinical use of serum c-erbB-2 in patients with ovarian masses. Gynecol Obstet Invest. 1999;48(2):133–7.

    CAS  PubMed  Google Scholar 

  45. Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, Watanabe A, Ochiai K, Yasuda M, Tanaka T. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol. 2004;94(3):735–9.

    CAS  PubMed  Google Scholar 

  46. Wong YF, Cheung TH, Lam SK, Lu HJ, Zhuang YL, Chan MY, Chung TK. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Gynecol Obstet Invest. 1995;40(3):209–12.

    CAS  PubMed  Google Scholar 

  47. Fan QB, Bian ML, Huang SZ, Lang JH, Ma J, Liu WS, Xu XY. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas. Chin Med J (Engl). 1994;107(8):589–93.

    CAS  Google Scholar 

  48. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard-Pedersen B, Hogdall CK. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003;98(1):66–73.

    CAS  PubMed  Google Scholar 

  49. Pfisterer J, Du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. Int J Gynecol Cancer. 2009;19(1):109–15.

    PubMed  Google Scholar 

  50. Nowee ME, Dorsman JC, Piek JM, Kosma VM, Hamalainen K, Verheijen RH, van Diest PJ. HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. Histopathology. 2007;51(5):666–73.

    CAS  PubMed  Google Scholar 

  51. Sasaki N, Kudoh K, Kita T, Tsuda H, Furuya K, Kikuchi Y. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma. J Obstet Gynaecol Res. 2007;33(1):17–23.

    CAS  PubMed  Google Scholar 

  52. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, Roman JJ, O’Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr, Pecorelli S. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer. 2004;90(9):1814–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  53. Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int J Gynecol Pathol. 2001;20(4):341–5.

    CAS  PubMed  Google Scholar 

  54. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W, Schauer A. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol. 1994;13(1):45–53.

    CAS  PubMed  Google Scholar 

  55. Tanner B, Kreutz E, Weikel W, Meinert R, Oesch F, Knapstein PG, Becker R. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol. 1996;62(2):268–77.

    CAS  PubMed  Google Scholar 

  56. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50(13):4087–91.

    CAS  PubMed  Google Scholar 

  57. Nijman HW, Kenemans P, Poort-Keesom RJ, Verstraeten RA, Mensdorff-Pouilly S, Verheijen RH, Melief CJ, Hilgers J, Meijer CJ. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999;83(2):201–6.

    CAS  PubMed  Google Scholar 

  58. Protopapas A, Diakomanolis E, Bamias A, Milingos S, Markaki S, Papadimitriou C, Dimopoulos AM, Michalas S. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Eur J Gynaecol Oncol. 2004;25(2):225–9.

    CAS  PubMed  Google Scholar 

  59. Hoopmann M, Sachse K, Valter MM, Becker M, Neumann R, Ortmann M, Gohring UJ, Thomas A, Mallmann P, Schondorf T. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. Eur J Cancer Care (Engl). 2010;19(6):809–15.

    CAS  Google Scholar 

  60. Abendstein B, Daxenbichler G, Windbichler G, Zeimet AG, Geurts A, Sweep F, Marth C. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res. 2000;20(1B):569–72.

    CAS  PubMed  Google Scholar 

  61. Bigsby RM, Li AX, Bomalaski J, Stehman FB, Look KY, Sutton GP. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol. 1992;79(1):95–100.

    CAS  PubMed  Google Scholar 

  62. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC Jr. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol. 1991;164(1 Pt 1):15–21.

    CAS  PubMed  Google Scholar 

  63. Coronado PJ, Vidart JA, Lopez-asenjo JA, Fasero M, Furio-bacete V, Magrina J, Escudero M. P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol. 2001;98(1):103–8.

    CAS  PubMed  Google Scholar 

  64. Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol. 2001;22(2):122–6.

    CAS  PubMed  Google Scholar 

  65. Cherchi PL, Marras V, Capobianco G, Ambrosini G, Piga MD, Fadda GM, Rosas N, Dessole S. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma. Eur J Gynaecol Oncol. 2001;22(6):451–3.

    CAS  PubMed  Google Scholar 

  66. Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C, Falchetti M, Fontana P, Grigolato PG, Pecorelli S. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer. 2008;18(1):14–21.

    CAS  PubMed  Google Scholar 

  67. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104(7):1391–7.

    CAS  PubMed  Google Scholar 

  68. Diaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol. 2006;100(1):139–44.

    CAS  PubMed  Google Scholar 

  69. Backe J, Gassel AM, Krebs S, Muller T, Caffier H. Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma. Arch Gynecol Obstet. 1997;259(4):189–95.

    CAS  PubMed  Google Scholar 

  70. Fanning J, Brown S, Phibbs G, Kramer T, Zaher A. Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer. Int J Gynecol Cancer. 2002;12(3):286–9.

    CAS  PubMed  Google Scholar 

  71. Wang D, Konishi I, Koshiyama M, Mandai M, Nanbu Y, Ishikawa Y, Mori T, Fujii S. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status. Cancer. 1993;72(9):2628–37.

    CAS  PubMed  Google Scholar 

  72. Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, Leelahakorn S, Pataradool K. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev. 2010;11(1):215–20.

    PubMed  Google Scholar 

  73. Hall J, Paul J, Brown R. Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med. 2004;6(12):1–20.

    PubMed  Google Scholar 

  74. Protrka Z, Mitrovic S, Arsenijevic N, Baskic D, Radosavljevic G, Stankovic M, Arsenijevic S. HER-2 expression in uterine cervix carcinogenesis. J BUON. 2007;12(1):91–7.

    CAS  PubMed  Google Scholar 

  75. Melczer Z, Banhidy F, Csomor S, Siklos P, Dworak O, Cseh K. ErbB-2/HER-2 protein expression, serum tumour necrosis factor-alpha (TFM-alpha) and soluble tumour necrosis factor receptor-2 (TNFR-2) concentrations in human carcinoma of the uterine cervix. Eur J Gynaecol Oncol. 2003;24(2):138–42.

    CAS  PubMed  Google Scholar 

  76. Ndubisi B, Sanz S, Lu L, Podczaski E, Benrubi G, Masood S. The prognostic value of HER-2/neu oncogene in cervical cancer. Ann Clin Lab Sci. 1997;27(6):396–401.

    CAS  PubMed  Google Scholar 

  77. Contreras DN, Cobos E, Lox CD. Evaluation of the circulating fraction of the HER-2/neu oncogene in patients with cervical cancer. Eur J Gynaecol Oncol. 2002;23(6):491–5.

    CAS  PubMed  Google Scholar 

  78. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Lauter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006;24(26):4317–23.

    CAS  PubMed  Google Scholar 

  79. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer. 2011;104(8):1241–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  80. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19(1):58–71.

    CAS  PubMed Central  PubMed  Google Scholar 

  81. Srinivasan R, Benton E, McCormick F, Thomas H, Gullick WJ. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res. 1999;5(10):2877–83.

    CAS  PubMed  Google Scholar 

  82. Fuchs I, Vorsteher N, Buhler H, Evers K, Sehouli J, Schaller G, Kummel S. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res. 2007;27(2):959–63.

    CAS  PubMed  Google Scholar 

  83. Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, Gaffney DK. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 2005;99(2):415–21.

    CAS  PubMed  Google Scholar 

  84. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst. 2013;105(4):266–73.

    CAS  PubMed  Google Scholar 

  85. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20(21):4292–302.

    CAS  PubMed  Google Scholar 

  86. Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM, Fischer EG, Leslie KK. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;124(3):569–74.

    CAS  PubMed  Google Scholar 

  87. Zhao S, Chen X, Lu X, Yu Y, Feng Y. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma. Gynecol Oncol. 2007;105(1):45–54.

    CAS  PubMed  Google Scholar 

  88. Ray-Coquard I, Guastalla JP, Allouache D, Combe M, Weber B, Cretin J, Curé H, Nunhuck S, Paraiso D, Mousseau M, Pujade-Lauraine E. HER2 overexpression/amplification and trastuzumab treatment in advanced ovarian cancer: a GINECO phase II study. Clin Ovarian Cancer. 2008;1(1):54–9.

    CAS  Google Scholar 

  89. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283–90.

    CAS  PubMed  Google Scholar 

  90. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(1):15–20.

    CAS  PubMed Central  PubMed  Google Scholar 

  91. Wilken JA, Maihle NJ. Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci. 2010;1210:53–65.

    CAS  PubMed Central  PubMed  Google Scholar 

  92. Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol. 2007;104(3):727–31.

    Google Scholar 

  93. Karamouzis MV, Badra FA, Papavassiliou AG. Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol. 2007;39(5):851–6.

    CAS  PubMed  Google Scholar 

  94. Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol. 2010;119(3):451–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  95. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96(22):1682–91.

    CAS  PubMed  Google Scholar 

  96. Hirte H, Oza A, Swenerton K, Ellard SL, Grimshaw R, Fisher B, Tsao M, Seymour L. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol. 2010;118(3):308–12.

    CAS  PubMed  Google Scholar 

  97. Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(3):493–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  98. Meng X, Laidler LL, Kosmacek EA, Yang S, Xiong Z, Zhu D, Wang X, Dai D, Zhang Y, Brachova P, Albitar L, Liu D, Ianzini F, Mackey MA, Leslie KK. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. Gynecol Oncol. 2013;128(3):461–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  99. Meng X, Yang S, Zhu D, Wang X, Thiel K, Leslie KL, Dizon D. Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53. Obstet Gynecol Int. 2013;2013:828165.

  100. Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, Bossi G. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem. 2010;285(19):14160–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  101. Behren A, Muhlen S, Acuna Sanhueza GA, Schwager C, Plinkert PK, Huber PE, Abdollahi A, Simon C. Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion. Oncogene. 2010;29(10):1519–30.

    CAS  PubMed  Google Scholar 

  102. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol. 2000;2(9):672–6.

    CAS  PubMed  Google Scholar 

  103. van Vugt MA, Smits VA, Klompmaker R, Medema RH. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. J Biol Chem. 2001;276(45):41656–60.

    PubMed  Google Scholar 

  104. Zhu H, Chang BD, Uchiumi T, Roninson IB. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by p21(WAF1/CIP1/SDI1). Cell Cycle. 2002;1(1):59–66.

    CAS  PubMed  Google Scholar 

  105. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, Nakagawara A. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem. 2004;279(24):25549–61.

    CAS  PubMed  Google Scholar 

  106. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET, Yu Q. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem. 2004;279(20):21183–92.

    CAS  PubMed  Google Scholar 

  107. Incassati A, Patel D, McCance DJ. Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6. Oncogene. 2006;25(17):2444–51.

    CAS  PubMed  Google Scholar 

  108. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA. 2009;106(10):3964–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  109. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29.

    CAS  PubMed  Google Scholar 

  110. McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, Robertson P, Bourdon JC, Perkins N, Fuller-Pace F, Meek DW. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle. 2010;9(20):4200–12.

    CAS  PubMed Central  PubMed  Google Scholar 

  111. Kaumaya PT, Foy KC. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 2012;8(8):961–87.

    CAS  PubMed  Google Scholar 

  112. Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE 3rd. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol. 2009;27(31):5270–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091–6.

    PubMed  Google Scholar 

  114. Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28(22):3562–9.

    CAS  PubMed  Google Scholar 

  115. Santin AD, Sill MW, McMeekin DS, Leitao MM Jr, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(3):495–500.

    CAS  PubMed Central  PubMed  Google Scholar 

  116. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;121(2):303–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  117. Goncalves A, Fabbro M, Lhomme C, Gladieff L, Extra JM, Floquet A, Chaigneau L, Carrasco AT, Viens P. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008;108(1):42–6.

    CAS  PubMed  Google Scholar 

  118. Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26(26):4319–25.

    CAS  PubMed  Google Scholar 

  119. Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2011;122(1):116–20.

    CAS  PubMed Central  PubMed  Google Scholar 

  120. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010;28(7):1215–23.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was partially supported by NIH 5K12HD063117-04 to H.D.R., R01CA99908-7 to K.K.L., the GOG Core Laboratory for Receptors and Targets funded by NIH CA27469, and the Department of Obstetrics and Gynecology Academic Enrichment Fund at the University of Iowa. The funding sources had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Conflict of interest

The authors declare no competing interests.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, 52242, USA

    Henry D. Reyes, Kristina W. Thiel, Matthew J. Carlson, Xiangbing Meng, Shujie Yang, Jean-Marie Stephan & Kimberly K. Leslie

  2. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, 52242, USA

    Xiangbing Meng & Kimberly K. Leslie

Authors
  1. Henry D. Reyes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristina W. Thiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew J. Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiangbing Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shujie Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Marie Stephan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kimberly K. Leslie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kimberly K. Leslie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reyes, H.D., Thiel, K.W., Carlson, M.J. et al. Comprehensive Profiling of EGFR/HER Receptors for Personalized Treatment of Gynecologic Cancers. Mol Diagn Ther 18, 137–151 (2014). https://doi.org/10.1007/s40291-013-0070-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-013-0070-3

Keywords

Search

Navigation